222 related articles for article (PubMed ID: 32482533)
1. Discovery of ORN0829, a potent dual orexin 1/2 receptor antagonist for the treatment of insomnia.
Futamura A; Suzuki R; Tamura Y; Kawamoto H; Ohmichi M; Hino N; Tokumaru Y; Kirinuki S; Hiyoshi T; Aoki T; Kambe D; Nozawa D
Bioorg Med Chem; 2020 Jul; 28(13):115489. PubMed ID: 32482533
[TBL] [Abstract][Full Text] [Related]
2. Oxadiazole Derivatives as Dual Orexin Receptor Antagonists: Synthesis, Structure-Activity Relationships, and Sleep-Promoting Properties in Rats.
Brotschi C; Roch C; Gatfield J; Treiber A; Williams JT; Sifferlen T; Heidmann B; Jenck F; Bolli MH; Boss C
ChemMedChem; 2019 Jul; 14(13):1257-1270. PubMed ID: 31066976
[TBL] [Abstract][Full Text] [Related]
3. Discovery of Highly Potent Dual Orexin Receptor Antagonists via a Scaffold-Hopping Approach.
Heidmann B; Gatfield J; Roch C; Treiber A; Tortoioli S; Brotschi C; Williams JT; Bolli MH; Abele S; Sifferlen T; Jenck F; Boss C
ChemMedChem; 2016 Oct; 11(19):2132-2146. PubMed ID: 27390287
[TBL] [Abstract][Full Text] [Related]
4. Identification of MK-8133: An orexin-2 selective receptor antagonist with favorable development properties.
Kuduk SD; Skudlarek JW; DiMarco CN; Bruno JG; Pausch MH; O'Brien JA; Cabalu TD; Stevens J; Brunner J; Tannenbaum PL; Garson SL; Savitz AT; Harrell CM; Gotter AL; Winrow CJ; Renger JJ; Coleman PJ
Bioorg Med Chem Lett; 2015 Jun; 25(12):2488-92. PubMed ID: 25981685
[TBL] [Abstract][Full Text] [Related]
5. Discovery of diazepane amide DORAs and 2-SORAs enabled by exploration of isosteric quinazoline replacements.
Roecker AJ; Mercer SP; Bergman JM; Gilbert KF; Kuduk SD; Harrell CM; Garson SL; Fox SV; Gotter AL; Tannenbaum PL; Prueksaritanont T; Cabalu TD; Cui D; Lemaire W; Winrow CJ; Renger JJ; Coleman PJ
Bioorg Med Chem Lett; 2015 Nov; 25(21):4992-4999. PubMed ID: 25613676
[TBL] [Abstract][Full Text] [Related]
6. Substituted pyrrolidin-2-ones: Centrally acting orexin receptor antagonists promoting sleep. Part 2.
Sifferlen T; Boller A; Chardonneau A; Cottreel E; Gatfield J; Treiber A; Roch C; Jenck F; Aissaoui H; Williams JT; Brotschi C; Heidmann B; Siegrist R; Boss C
Bioorg Med Chem Lett; 2015 May; 25(9):1884-91. PubMed ID: 25838147
[TBL] [Abstract][Full Text] [Related]
7. The Quest for the Best Dual Orexin Receptor Antagonist (Daridorexant) for the Treatment of Insomnia Disorders.
Boss C; Gatfield J; Brotschi C; Heidmann B; Sifferlen T; von Raumer M; Schmidt G; Williams JT; Treiber A; Roch C
ChemMedChem; 2020 Dec; 15(23):2286-2305. PubMed ID: 32937014
[TBL] [Abstract][Full Text] [Related]
8. From Oxadiazole to Triazole Analogues: Optimization toward a Dual Orexin Receptor Antagonist with Improved in vivo Efficacy in Dogs.
Brotschi C; Bolli MH; Gatfield J; Heidmann B; Jenck F; Roch C; Sifferlen T; Treiber A; Williams JT; Boss C
ChemMedChem; 2020 Mar; 15(5):430-448. PubMed ID: 31945272
[TBL] [Abstract][Full Text] [Related]
9. Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia.
Roecker AJ; Reger TS; Mattern MC; Mercer SP; Bergman JM; Schreier JD; Cube RV; Cox CD; Li D; Lemaire W; Bruno JG; Harrell CM; Garson SL; Gotter AL; Fox SV; Stevens J; Tannenbaum PL; Prueksaritanont T; Cabalu TD; Cui D; Stellabott J; Hartman GD; Young SD; Winrow CJ; Renger JJ; Coleman PJ
Bioorg Med Chem Lett; 2014 Oct; 24(20):4884-90. PubMed ID: 25248679
[TBL] [Abstract][Full Text] [Related]
10. Discovery of dual orexin receptor antagonists with rat sleep efficacy enabled by expansion of the acetonitrile-assisted/diphosgene-mediated 2,4-dichloropyrimidine synthesis.
Roecker AJ; Mercer SP; Harrell CM; Garson SL; Fox SV; Gotter AL; Prueksaritanont T; Cabalu TD; Cui D; Lemaire W; Winrow CJ; Renger JJ; Coleman PJ
Bioorg Med Chem Lett; 2014 May; 24(9):2079-85. PubMed ID: 24704030
[TBL] [Abstract][Full Text] [Related]
11. Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia.
Roecker AJ; Cox CD; Coleman PJ
J Med Chem; 2016 Jan; 59(2):504-30. PubMed ID: 26317591
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and structure-activity relationships of a series of novel N-aryl-2-phenylcyclopropanecarboxamide that are potent and orally active orexin receptor antagonists.
Yoshida Y; Terauchi T; Naoe Y; Kazuta Y; Ozaki F; Beuckmann CT; Nakagawa M; Suzuki M; Kushida I; Takenaka O; Ueno T; Yonaga M
Bioorg Med Chem; 2014 Nov; 22(21):6071-88. PubMed ID: 25267004
[TBL] [Abstract][Full Text] [Related]
13. Discovery and development of orexin receptor antagonists as therapeutics for insomnia.
Winrow CJ; Renger JJ
Br J Pharmacol; 2014 Jan; 171(2):283-93. PubMed ID: 23731216
[TBL] [Abstract][Full Text] [Related]
14. Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia.
Cox CD; Breslin MJ; Whitman DB; Schreier JD; McGaughey GB; Bogusky MJ; Roecker AJ; Mercer SP; Bednar RA; Lemaire W; Bruno JG; Reiss DR; Harrell CM; Murphy KL; Garson SL; Doran SM; Prueksaritanont T; Anderson WB; Tang C; Roller S; Cabalu TD; Cui D; Hartman GD; Young SD; Koblan KS; Winrow CJ; Renger JJ; Coleman PJ
J Med Chem; 2010 Jul; 53(14):5320-32. PubMed ID: 20565075
[TBL] [Abstract][Full Text] [Related]
15. Preclinical in vivo characterization of lemborexant (E2006), a novel dual orexin receptor antagonist for sleep/wake regulation.
Beuckmann CT; Ueno T; Nakagawa M; Suzuki M; Akasofu S
Sleep; 2019 Jun; 42(6):. PubMed ID: 30923834
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological characterization of a novel potent, selective, and orally active orexin 2 receptor antagonist, SDM-878.
Maehara S; Yuge N; Higashi C; Ota T; Furukawa J; Takeuchi T
Neuropsychopharmacol Rep; 2020 Jun; 40(2):182-189. PubMed ID: 32337858
[TBL] [Abstract][Full Text] [Related]
17. Discovery and in vitro and in vivo profiles of N-ethyl-N-[2-[3-(5-fluoro-2-pyridinyl)-1H-pyrazol-1-yl]ethyl]-2-(2H-1,2,3-triazol-2-yl)-benzamide as a novel class of dual orexin receptor antagonist.
Suzuki R; Nozawa D; Futamura A; Nishikawa-Shimono R; Abe M; Hattori N; Ohta H; Araki Y; Kambe D; Ohmichi M; Tokura S; Aoki T; Ohtake N; Kawamoto H
Bioorg Med Chem; 2015 Mar; 23(6):1260-75. PubMed ID: 25693785
[TBL] [Abstract][Full Text] [Related]
18. The Discovery of Suvorexant, the First Orexin Receptor Drug for Insomnia.
Coleman PJ; Gotter AL; Herring WJ; Winrow CJ; Renger JJ
Annu Rev Pharmacol Toxicol; 2017 Jan; 57():509-533. PubMed ID: 27860547
[TBL] [Abstract][Full Text] [Related]
19. Investigation of New Orexin 2 Receptor Modulators Using
Janockova J; Dolezal R; Nepovimova E; Kobrlova T; Benkova M; Kuca K; Konecny J; Mezeiova E; Melikova M; Hepnarova V; Ring A; Soukup O; Korabecny J
Molecules; 2018 Nov; 23(11):. PubMed ID: 30423961
[TBL] [Abstract][Full Text] [Related]
20. Structure-activity relationship, biological, and pharmacological characterization of the proline sulfonamide ACT-462206: a potent, brain-penetrant dual orexin 1/orexin 2 receptor antagonist.
Boss C; Roch-Brisbare C; Steiner MA; Treiber A; Dietrich H; Jenck F; von Raumer M; Sifferlen T; Brotschi C; Heidmann B; Williams JT; Aissaoui H; Siegrist R; Gatfield J
ChemMedChem; 2014 Nov; 9(11):2486-96. PubMed ID: 25147058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
